TB-500 in Australia: what the research actually shows

The short answer

TB-500 is a synthetic peptide fragment that research sources commonly describe as corresponding to the actin-binding region of thymosin beta-4. It is studied in preclinical and animal models, not approved by the TGA, not listed on the ARTG, and is supplied in Australia for laboratory research use only. It is prohibited in sport at all times under the WADA Prohibited List.

What TB-500 is

Thymosin beta-4 (often written as Tbeta4 or TB4) is a naturally occurring protein of around 43 amino acids. TB-500 is the name most commonly applied in the research-chemical market to a shorter synthetic peptide fragment that is generally described as corresponding to the actin-binding portion of thymosin beta-4, centred on a short sequence often written as LKKTETQ.

It is worth noting that the label TB-500 is used loosely in the marketplace. Some material is described as the short synthetic fragment, while full-length thymosin beta-4 is a distinct, larger molecule. Researchers should treat the two as related but not identical, and should rely on independent characterisation rather than the trade name alone.

How it is usually framed in the literature

• A synthetic peptide fragment associated with the actin-binding region of thymosin beta-4
• Distinct from the full-length thymosin beta-4 protein
• Studied in cell and animal models, not in approved human therapy
• Sold on the research-chemical market under the TB-500 label

Mechanism and what the research actually shows

In preclinical work, thymosin beta-4 and related fragments are described as binding monomeric actin (G-actin), which influences the pool of actin available for building the cytoskeleton. Through this and related pathways, the literature discusses roles in cell migration, blood vessel formation (angiogenesis) and tissue-repair processes in laboratory models.

The key point for anyone reading the marketing is that the evidence base is overwhelmingly preclinical. Published studies have largely been conducted in cell cultures and animals. There are very limited or no completed, published human efficacy trials for the TB-500 fragment. Nothing here should be read as proof that the compound does anything in people.

Areas investigated in preclinical models

• Actin binding and cytoskeletal dynamics
• Cell migration in wound-model experiments
• Angiogenesis, meaning blood-vessel formation
• Tissue-repair and inflammation-modulation pathways

Research compound versus approved medicine

An approved medicine has passed clinical trials, carries a quality standard, and appears on the Australian Register of Therapeutic Goods (ARTG) with approved indications. TB-500 does not meet any of these criteria. It is not registered on the ARTG, it is not approved by the TGA for human therapeutic use, and no commercially manufactured ARTG-listed TB-500 product exists for any indication.

That distinction matters. A research compound is characterised for laboratory investigation, not formulated, tested or labelled for use in people or animals. Marketing that presents TB-500 as a recovery or healing product is making claims that regulators have not accepted.

What research use only (RUO) means

Research use only means a compound is intended strictly for laboratory and scientific investigation by qualified researchers. It is not a therapeutic good. It is not for human or animal consumption, and it is not intended to diagnose, treat, cure or prevent anything.

RUO in practice

• For in-vitro and laboratory research by qualified parties only
• Not for human or veterinary use
• No dosing, reconstitution or administration guidance is provided
• Supplied with no therapeutic or performance claims

TB-500 and sport (WADA and Sport Integrity Australia)

TB-500 and thymosin beta-4 are prohibited in sport at all times, both in and out of competition, under the WADA Prohibited List. Sport Integrity Australia lists thymosin beta-4 within the peptide hormones, growth factors, related substances and mimetics class (the S2 group), under the growth factors and growth factor modulators heading.

For any athlete subject to the WADA Code, the presence or use of TB-500 can result in an anti-doping rule violation. This is one of the most important facts for Australian readers to understand before handling the compound in any context near sport.

Regulatory status in Australia

In Australia, medicines and poisons are classified under the Poisons Standard. Public sources, including Healthy Male and Sport Integrity Australia, describe TB-500 and thymosin beta-4 as being handled as prescription-only (Schedule 4) following a scheduling decision that took effect in 2024, while noting that no approved, ARTG-registered product exists for these compounds.

Because the scheduling position and supply rules can change, this guide does not reproduce legal advice or importation steps. Anyone considering importing or possessing scheduling-controlled substances should confirm the current position with the TGA and seek their own legal advice. NovaPeptides supplies TB-500 for laboratory research use only and makes no representation about individual circumstances.

How NovaPeptides supplies TB-500

NovaPeptides supplies TB-500 strictly for laboratory research use only. Products are independently verified, listed with their specification, and dispatched within Australia. We do not provide dosing, reconstitution guidance, protocols, or any therapeutic, recovery or performance claims, because the compound is not a medicine and is not for human or animal use.

What we provide

• Research-use-only supply with no medical or performance claims
• Independently verified material
• Shipping within Australia
• WhatsApp enquiries for research-related product questions

If you are a qualified researcher with questions about specification or availability, reach out via WhatsApp. We cannot advise on human or veterinary use, and we do not provide dosing information.

Frequently asked questions